Q4 2025 Women’s Health and Menopause Treatment Initiatives

Sprout Pharmaceuticals advanced an initiative to drive HSDD awareness while highlighting regulatory milestones for Addyi to reduce access barriers and expand use to postmenopausal women.

Mayne Pharma positioned Bijuva through “The One” campaign as a single-capsule bioidentical HRT for moderate to severe menopausal vasomotor symptoms, supported by copay programs, pharmacy partnerships, and Bijuva Support services to improve access.

Imvexxy messaging was used to normalize intimacy after menopause and encourage conversations about VVA-related dyspareunia, highlighting low-dose estradiol vaginal inserts as a localized ERT option.

Bayer introduced Lynkuet (elinzanetant) following FDA approval as a first-in-class hormone-free treatment for menopausal vasomotor symptoms, supported by clinical data and access initiatives.